Given the high correlation of pCR and clinical outcomes, both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) endorsed the use of pCR as an endpoint for the assessment of neoadjuvant treatment for HER2-positive and TN disease breast cancer patients [11,12]. This evidence concerns the gene ERBB2 and breast carcinoma.